Search Results for "Skin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Skin. Results 101 to 110 of 123 total matches.

Guselkumab (Tremfya) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2025  (Issue 1724)
fungal skin infections and herpes simplex infections, have occurred in patients treated with the drug ...
The interleukin (IL)-23 antagonist guselkumab (Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was approved earlier for treatment of plaque psoriasis and psoriatic arthritis. Guselkumab is the third IL-23 antagonist to be approved in the US for treatment of UC; risankizumab (Skyrizi) and mirikizumab (Omvoh) were approved earlier.
Med Lett Drugs Ther. 2025 Mar 17;67(1724):46-8   doi:10.58347/tml.2025.1724d |  Show IntroductionHide Introduction

Drugs for Treatment and Prevention of Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
Unfractionated heparin (UFH) Heparin-induced thrombocytopenia, skin necrosis, urticaria, increased liver ...
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for treatment of VTE were updated in 2020 and 2021.
Med Lett Drugs Ther. 2022 Jul 25;64(1655):113-20 |  Show IntroductionHide Introduction

Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
can occur; cytopenias are rare Increased risk of serious infections; tuberculin skin testing ...
View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis
Med Lett Drugs Ther. 2021 Nov 15;63(1637):e187-9 |  Show IntroductionHide Introduction

Tirzepatide (Mounjaro) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022  (Issue 1654)
receptor agonists. Skin reactions and serious hypersensitivity reactions such as anaphylaxis ...
The FDA has approved tirzepatide (Mounjaro – Lilly), a peptide hormone with activity at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, to improve glycemic control in adults with type 2 diabetes. Tirzepatide, which is injected subcutaneously once weekly, is the first dual GIP/GLP-1 receptor agonist to become available in the US. Selective GIP receptor agonists are not available in the US; GLP-1 receptor agonists have been available for years.
Med Lett Drugs Ther. 2022 Jul 11;64(1654):105-7 |  Show IntroductionHide Introduction

Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis

   
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023  (Issue 1669)
and is associated with HIV infection.6 Standard Treatment – Skin hydration with regular use of emollients ...
The FDA has approved the subcutaneously injected interleukin (IL)-4 receptor alpha antagonist dupilumab (Dupixent – Sanofi/Regeneron) for treatment of eosinophilic esophagitis (EoE) in patients ≥12 years old who weigh ≥40 kg and treatment of prurigo nodularis in adults. Dupilumab is the first drug to be approved in the US for each of these indications. It is also FDA-approved for treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):18-20   doi:10.58347/tml.2023.1669b |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Gout (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023  (Issue 1688)
of cyclosporine Can prolong the half-life of chlorpropamide May increase frequency of skin rash in patients ...
View the Comparison Table: Some Drugs for Gout
Med Lett Drugs Ther. 2023 Oct 30;65(1688):e176-9   doi:10.58347/tml.2023.1688c |  Show IntroductionHide Introduction

Drugs for Open-Angle Glaucoma

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025  (Issue 1727)
, and an increase in periorbital skin pigmentation. PGAs may also cause local irritation, itching, dryness ...
Glaucoma is a progressive optic neuropathy associated with increased intraocular pressure (IOP; normal range 8-22 mm Hg), which is the only disease-related factor that can be modified. Topical drugs that lower IOP are the first line of treatment for open-angle glaucoma.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):65-8   doi:10.58347/tml.2025.1727a |  Show IntroductionHide Introduction

Comparison Table: Inhaled Drugs for Treatment of COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024  (Issue 1710)
and dysphonia ▶ Systemic absorption has been associated with skin bruising, cataracts, reduced bone mineral ...
View the Comparison Table: Inhaled Drugs for Treatment of COPD
Med Lett Drugs Ther. 2024 Sep 2;66(1710):e143-7   doi:10.58347/tml.2024.1710b |  Show IntroductionHide Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • May 15, 2023  (Issue 1676)
with oral contraceptives. Skin irritation at the application site can occur and may lead ...
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also effective in preventing pregnancy. When used alone, barrier and behavioral methods generally have higher failure rates than other methods (see Table 1). Selection of a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80   doi:10.58347/tml.2023.1676a |  Show IntroductionHide Introduction

Drugs for Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • Jan 06, 2025  (Issue 1719)
during the infusion. The skin and eyes of patients who receive verteporfin may be sensitive to sunlight ...
Age-related macular degeneration (AMD) has two major forms: dry or non-neovascular (~90% of patients) and wet or neovascular (~10% of patients).
Med Lett Drugs Ther. 2025 Jan 6;67(1719):1-5   doi:10.58347/tml.2025.1719a |  Show IntroductionHide Introduction